Evaluation of FGF-23 Suppressibility by Calcitonin in Healthy Men - Pilot Study
N/A
20 Years
55 Years
20 Years
55 Years
Open (Enrolling)
Male
Hypophosphatemia
Male
Hypophosphatemia
Trial Information
Evaluation of FGF-23 Suppressibility by Calcitonin in Healthy Men - Pilot Study
Inclusion Criteria:
- Healthy man, who are between 20-55 years old, and have a BMI 20-27 kg/m2.
Exclusion Criteria:
- Serum creatinin >100 mmol/L, or glomerular filtration rate <80 ml/min.
- Abnormal serum Ca, PO4, albumin, 25-OH vitamin D, or PTH levels.
- Any medication.
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science
Outcome Measure:
A change of 25% in de serum FGF-23 levels in response to a single subcutaneous injection of calcitonin 200 IU.
Outcome Time Frame:
eight hours
Safety Issue:
No
Authority:
Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
Study ID:
LTC-524/030408
NCT ID:
NCT00688077
Start Date:
May 2008
Completion Date:
Related Keywords:
- Hypophosphatemia
- Fibroblast growth factor - 23
- Calcitonin
- Hypophosphatemia
Name | Location |
|---|
